Management of SPN in France. Pathways for definitive diagnosis of solitary pulmonary nodule: a multicentre study in 18 French districts-0

Aspiration biopsy; Wang: Wang needle biopsy; SUR: surgery; CRT: chemoradiotherapy).<p><b>Copyright information:</b></p><p>Taken from "Management of SPN in France. Pathways for definitive diagnosis of solitary pulmonary nodule: a multicentre study in 18 French districts"</p><p>http://www.biomedcentral.com/1471-2407/8/93</p><p>BMC Cancer 2008;8():93-93.</p><p>Published online 10 Apr 2008</p><p>PMCID:PMC2373300.</p><p></p

Quality of life data collection procedure.

<p>Quality of life data collection procedure.</p

Multivariate cox regression analyses of time to QoL score deterioration for factors influencing significantly TTD.

<p><b>N</b>: number of subjects.</p><p><b>NA</b>: not applicable (variable not included in the model).</p><p><b>CI</b>: confidence interval.</p

Time to deterioration in QoL score in the studied population with response shift (RS) taken into account or not.

<p>a) for the general health score of the QLQ-C30. b) for the role functioning score of the QLQ-C30. c) for emotional functioning. d)for social functioning. e) for body image. f) for systematic therapy side effects.</p

Median TTD according recalibration of response shift.

<p>Then-test 1: retrospective assessment of baseline at the end of 1st hospitalization.</p><p>Then-test 2: retrospective assessment of baseline at 3 months.</p><p>Then-test 3: retrospective assessment of 3-month QoL.</p>†<p>then-test2.</p>¥<p>then-test1 & then-test3 (i.e. significant recalibration was also observed at the retrospective assessment of 3-month QoL).</p>?<p>then-test2 & then-test3 (i.e. significant recalibration was also observed at the retrospective assessment of 3-month QoL).</p>‡<p>then-test3.</p><p>NA: Not applicable (no significant recalibration).</p><p>NR: Not reached.</p><p>Inf: Infinite.</p

Characteristics of patients according to the completion of quality of life questionnaire at baseline.

<p>Characteristics of patients according to the completion of quality of life questionnaire at baseline.</p

Additional file 1: Table S1. of Impact of the occurrence of a response shift on the determination of the minimal important difference in a health-related quality of life score over time

The Response shift effect for the QLQ-C30 questionnaire after three and six months for all patients and according to each category of the anchor. Table S2. The Response shift effect for the QLQ-BR23 questionnaire after three and six months for all patients and according to each category of the anchor. Table S3. Observed and adjusted changes of the QLQ–C30 questionnaire after three and six months. Table S4. Observed and adjusted changes of the QLQ–BR23 questionnaire after three and six months. (DOCX 95 kb

Intraepidermal nerve fiber density (IENFD) normative values for clinical use.

<p>Intraepidermal nerve fiber density (IENFD) normative values for clinical use.</p

Merkel cells following PGP 9.5 immunolabeling.

<p>A-B: Isolated Merkel cells or touch dome in the basal epidermal layer; C-D: Epidermal cluster of Merkel cells; B and D show that only nerve terminals filled with mitochondria are immunolabeled.</p

Flow chart indicating the number of healthy subjects and biopsies analyzed in the study.

<p>Twenty-seven volunteers failed screening for inclusion in the study. Among them, 23 subjects were at risk of neuropathy for reasons that included diabetes, renal insufficiency, positive serology for HCV or HBV, and absence of deep tendon reflex. Four subjects had a contraindication to skin biopsy (HTA [xylocaine injection], limb surgery, pregnancy, or prohibited therapy).</p